Latest Shareholder Value News

Australian Clinical Labs has announced a 12-month on-market share buy-back program targeting up to 10% of its shares, aiming to enhance shareholder returns without compromising its financial strength.

Vault Minerals delivered a strong September quarter with record gold production and advancing key infrastructure upgrades, setting the stage for significant free cash flow growth in FY27.

Regis Resources reported a solid September quarter with 90.4koz gold production and a $158 million increase in cash and bullion. Key underground projects at Garden Well Main and Rosemont Stage 3 began ore production, supporting steady FY26 guidance.

Deterra Royalties announces the resignation of CEO Julian Andrews by year-end, with Non-executive Director Jason Neal stepping in as interim CEO amid a search for a permanent replacement.

Heartland Group Holdings reported a solid first quarter for FY2026, with improved profitability, stable costs, and accelerated realisation of non-strategic assets surpassing expectations.

Australis Oil & Gas reported a modest dip in production volumes for Q3 2025 but offset this with higher realised oil prices and disciplined cost management. The company remains focused on securing a development partner to unlock the full potential of its Tuscaloosa Marine Shale assets.

Restaurant Brands New Zealand advises shareholders to hold off on responding to Finaccess's takeover offer until the Target Company Statement is released, promising clearer guidance by late October.

Michael Hill International reported flat earnings in FY25 amid inflation and subdued demand, while new CEO Jonathan Waecker outlines a strategy focused on innovation, AI integration, and margin recovery heading into FY26.

Dateline Resources’ Managing Director Stephen Baghdadi has increased his personal investment by exercising 13.86 million options, reinforcing confidence in the Colosseum Gold and Rare Earth Elements Project as feasibility studies progress.

MedAdvisor Solutions reported a steep 52.8% revenue decline in Q1 FY26, impacted by US regulatory pressures and vaccine program delays, while embarking on a strategic transformation to restore growth.

MedAdvisor reports a sharp 53% drop in 1Q FY26 revenue driven by U.S. regulatory and sector challenges, while advancing a major platform transformation and selling its ANZ business to emerge debt-free.

Vitasora Health has received $2.43 million from a cornerstone investor, advancing its $11 million capital raise and reinforcing its path to profitability by Q4 FY2026. The company’s expanding US partnerships and technology investments signal growing market confidence.